Integrum AB Class B (SE:INTEG.B)
:INTEG.B
Top Page
Integrum AB Class B
(INTEG.B)
Select Model
Select Model
Rating:42Neutral
Price Target:
kr6.50
▼(-37.50% Downside)
Action:ReiteratedDate:03/08/26
The score is primarily held down by weak financial performance (losses and negative/deteriorating free cash flow) despite a low-debt balance sheet. Technicals add further pressure with price below key moving averages and negative MACD. Valuation provides limited support due to a negative P/E and no dividend yield data.
Positive Factors
Specialized product niche
Integrum operates in a narrow, high-barrier medical niche—osseointegration implants for amputees—which relies on specialized clinical centers. This focused product line and clinical orientation create durable differentiation and patient-specific demand that supports long-term revenue visibility and clinical adoption cycles.
Negative Factors
Negative cash generation
Persistent negative operating and free cash flow is a structural pressure that increases funding risk and may necessitate dilutive equity raises or constrained investment. For a small med-tech, ongoing cash burn limits ability to scale commercialization and prolongs the timeline to achieve self-sustaining operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized product niche
Integrum operates in a narrow, high-barrier medical niche—osseointegration implants for amputees—which relies on specialized clinical centers. This focused product line and clinical orientation create durable differentiation and patient-specific demand that supports long-term revenue visibility and clinical adoption cycles.
Read all positive factors
Integrum AB Class B (INTEG.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr191.74M
Dividend YieldN/A
Average Volume (3M)674.44K
Price to Earnings (P/E)―
Beta (1Y)0.57
Revenue Growth0.62%
EPS Growth-82.70%
CountrySE
Employees36
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.47
Shares Outstanding26,027,910
10 Day Avg. Volume474,857
30 Day Avg. Volume674,441
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.64
Price to Sales (P/S)3.20
P/FCF Ratio-5.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Integrum AB Class B Business Overview & Revenue Model
Company Description
Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on ...
How the Company Makes Money
Integrum makes money primarily by selling its osseointegration implant system and related prosthetic connection components (including implants and associated hardware) used in surgical treatment and long-term rehabilitation of amputees. Revenue is...
Integrum AB Class B Financial Statement Overview
Summary
Income Statement
36
Negative
Balance Sheet
74
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 93.48M | 91.10M | 104.12M | 74.27M | 55.72M | 43.09M |
| Gross Profit | 16.42M | 75.38M | 91.26M | 60.84M | 46.56M | 34.89M |
| EBITDA | -37.56M | -35.50M | 8.76M | -20.24M | 2.60M | -1.59M |
| Net Income | -37.87M | -30.85M | 4.03M | -16.18M | 21.27M | -2.14M |
Balance Sheet | ||||||
| Total Assets | 206.17M | 203.25M | 164.86M | 165.17M | 180.44M | 37.21M |
| Cash, Cash Equivalents and Short-Term Investments | 30.17M | 39.60M | 16.90M | 41.92M | 75.34M | 7.66M |
| Total Debt | 3.60M | 4.84M | 6.42M | 7.92M | 580.89K | 1.54M |
| Total Liabilities | 23.65M | 25.38M | 22.07M | 21.64M | 20.70M | 12.91M |
| Stockholders Equity | 182.52M | 177.88M | 142.79M | 143.53M | 159.74M | 24.29M |
Cash Flow | ||||||
| Free Cash Flow | -43.53M | -50.59M | -24.37M | -36.50M | -49.55M | -7.47M |
| Operating Cash Flow | -38.46M | -37.70M | -12.74M | -25.10M | -20.28M | -5.76M |
| Investing Cash Flow | -12.08M | -12.89M | -11.63M | -11.40M | -29.27M | -1.71M |
| Financing Cash Flow | 66.07M | 73.29M | -648.54K | 3.08M | 117.23M | 2.06M |
Integrum AB Class B Technical Analysis
Negative
10.40
Price Trends
8.28
Negative
9.19
Negative
17.31
Negative
Market Momentum
-0.39
Negative
35.79
Neutral
23.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:INTEG.B, the sentiment is Negative. The current price of 10.4 is above the 20-day moving average (MA) of 7.51, above the 50-day MA of 8.28, and below the 200-day MA of 17.31, indicating a bearish trend. The MACD of -0.39 indicates Negative momentum. The RSI at 35.79 is Neutral, neither overbought nor oversold. The STOCH value of 23.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:INTEG.B.
Integrum AB Class B Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | kr381.10M | -11.61 | -27.25% | ― | -0.02% | -85.98% | |
55 Neutral | kr881.32M | 103.06 | 6.93% | ― | -5.80% | -65.99% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr664.23M | -5.78 | -36.55% | ― | 62.24% | 21.16% | |
48 Neutral | kr303.86M | -6.28 | -104.38% | ― | 21.88% | 48.86% | |
46 Neutral | kr586.99M | 13.94 | -2.52% | ― | -8.10% | 62.08% | |
42 Neutral | kr191.74M | -5.27 | -18.55% | ― | 0.62% | -82.70% |
* Healthcare Sector Average
SE:INTEG.B
Integrum AB Class B
7.19
-6.04
-45.65%
SE:SEZI
Senzime AB
4.23
0.37
9.60%
SE:BACTI.B
Bactiguard Holding AB
16.75
-14.55
-46.49%
SE:CRAD.B
C-Rad AB Class B
26.10
-0.60
-2.25%
SE:ACARIX
Acarix AB
0.27
0.05
22.17%
SE:MNTC
Mentice AB
13.55
-4.25
-23.86%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.